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Aim To determine the frequency of inherited and acquired 
prothrombotic risk factors in children with arterial ischemic 
stroke (AIS) and transient ischemic attacks (TIA) in Croatia.
Methods We investigated 14 prothrombotic risk factors 
using blood samples from 124 children with AIS or TIA and 
42 healthy children. Prothrombotic risk factors were classi-
fied into five groups: natural coagulation inhibitors (anti-
thrombin, protein C, protein S), blood coagulation factors 
(FV Leiden and FII 20210), homocysteine, lipid and lipopro-
tein profile (lipoprotein (a), triglycerides, total, high- and 
low-density lipoprotein), and antiphospholipid antibodies 
(lupus anticoagulant, anticardiolipin, and antiphosphati-
dylserine antibodies).
Results The most common prothrombotic risk factor was 
elevated lipoprotein (a), which was identified in about 31% 
of patients and in 24% of controls. Natural coagulation in-
hibitors were decreased in about 19% of patients, but not 
in controls. Pathological values of homocysteine, blood 
coagulation factor polymorphisms, and antiphospholipid 
antibodies were found in similar frequencies in all groups. 
Fourteen children with AIS and TIA (11.3%) and no children 
from the control group had three or more investigated risk 
factors.
Conclusion The presence of multiple prothrombotic risk 
factors in children with cerebrovascular disorder suggests 
that a combination of risk factors rather than individual risk 
factors could contribute to cerebrovascular disorders in 
children. Received: January 10, 2013
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Stroke in children is a heterogeneous disorder, increasingly 
recognized as an important cause of childhood disability 
and lifelong morbidity (1). In up to one third of children 
with arterial ischemic stroke (AIS), preceding transient isch-
emic attacks (TIA) are present, although they are frequently 
not diagnosed (2).
The frequency of ischemic stroke in children may be great-
er than previously suggested, as reported in a recent study 
performed in a cohort of North Californian children, which 
found a two to four times higher frequency than previously 
estimated in the US (3). Recent estimates have suggested 
that ischemic stroke in children occurs at much higher rate 
soon after birth than later in childhood: in about 1 per 4000 
live births in the US (4). In Croatia, the yearly incidence of 
AIS in children is 0.67 cases per 100 000 (5).
Although modern technology allows accurate definition 
of the presence and type of stroke, in up to one third of 
children the etiology still remains undetermined (6). Con-
ditions associated with childhood AIS include a great va-
riety of diseases such as cardiac disease, hematological 
disorders, cerebral arteriopathies, trauma, infections, met-
abolic diseases, and collagen tissue abnormalities (1,6,7). 
In addition, hypercoagulable states associated with dif-
ferent inherited or acquired prothrombotic disorders are 
being increasingly recognized as possible risk factors for 
AIS (8).
The most studied prothrombotic risk factors include de-
ficiencies of natural coagulation inhibitors such as anti-
thrombin III, protein C, and free protein S, and genetic 
polymorphisms encoding proteins that constitute the co-
agulation system: factor V Leiden (FVL) and factor II 20210A 
(FII 20210A). Furthermore, hyperhomocysteinemia, elevat-
ed lipoprotein (a) values, and the presence of antiphos-
pholipid antibodies (APA) have been reported as addition-
al prothrombotic risk factors (8-13). Although individual 
prothrombotic risk factors are less important risk factors for 
childhood stroke, the presence of multiple prothrombotic 
risk factors may increase its risk (1,9).
The distribution of prothrombotic risk factors may vary 
among different age groups, stroke subtypes, and different 
populations (14). The aim of the present study was to de-
termine the frequency of common inherited and acquired 
prothrombotic risk factors in Croatian children with an es-
tablished diagnosis of AIS and TIA of undetermined etiol-
ogy, and to identify possible cases of presence of multiple 
risk factors in children with AIS and TIA.
PAtients/MAteRiAL AnD MetHoDs
This research was performed as a part of a large clinical 
observation study (the project approved by the Ministry 
of Science of Croatia) on the role and prevalence of pro-
thrombotic risk factors in children with cerebrovascular 
events.
Participants
From September 2000 to June 2007, 161 children with 
symptoms of focal neurological deficit were admitted to 
the Department of Neuropediatrics at the Children’s Hos-
pital Zagreb. Also, 18 asymptomatic children were referred 
from primary care health center due to medical history 
of suspected TIA. Asymptomatic patients were admitted 
to the hospital within 48 hours of the onset of symptoms 
indicating an acute cerebrovascular event. Children who 
showed no symptoms at the admission were diagnosed 
with TIA and kept at the Neuropediatric Department for 
observation in the same way as the children admitted with 
the symptoms.
Of the initial 179 children, aged ≤18 years, from different 
regions of Croatia, 55 children (30.7%) were excluded (Fig-
ure 1). In 41 children, the diagnosis of AIS or TIA was not 
confirmed and in 14 children blood sampling was not 
done successfully or completely. Finally, 124 children were 
included in the study (47 children with AIS and 77 children 
with TIA). The control group consisted of 42 children (32 
boys, 10 girls) aged ≤18 years from the same region with 
no history of neurologic or thromboembolic diseases, who 
were recruited among children waiting a minor surgery 
(adenotonsillectomy). The informed consent was obtained 
from the parents, and the study was approved by the eth-
ics committee of Children’s Hospital Zagreb.
inclusion/exclusion criteria
During the hospital stay, the diagnosis was established on 
the basis of careful clinical history-taking and physical and 
neurological examinations, and documented with at least 
one brain imaging technique, computed tomography (CT) 
or magnetic resonance imaging (MRI). Furthermore, elec-
troencephalographic (EEG) examinations, transcranial col-
or Doppler ultrasonography (TCCD), and a panel of rou-
tine laboratory tests (complete blood count, erythrocyte 
sedimentation rate, C-reactive protein, global coagula-
tion test, acid-base status, global biochemistry panel, 
and routine urine examination) were performed.
CLINICAL SCIENCE348 Croat Med J. 2013;54:346-54
www.cmj.hr
Inclusion criteria for this study were clinical symptoms of 
AIS/TIA in children: hemiparesis or monoparesis, seizures, 
headache, spasticity, hypotonia, vomiting, aphasia, vertigo, 
and/or ataxia. Brain imaging technique (CT and/or MRI) was 
performed in all patients. If radiologic evidence of cerebral 
infarction in arterial distribution was present, the diagno-
sis of AIS was established. Otherwise, detailed examination 
(EEG, TCCD, routine laboratory tests) was performed to rule 
out migraine, seizure, encephalitis, traumatic hemorrhage, 
and/or tumor, thus establishing the diagnosis of TIA.
Control participants were children from the same geo-
graphical region as patients, hospitalized during the same 
period. All children underwent routine preoperative ex-
amination that included radiological imaging of the heart 
and lungs, electrocardiography, as well as a panel of rou-
tine laboratory tests (complete blood count, erythrocyte 
sedimentation rate, global coagulation test, acid-base sta-
tus, global biochemistry panel, and routine urine examina-
tion) and examination by anesthesiologist. The study in-
cluded only healthy children, who received the approval of 
an anesthesiologist. Exclusion criteria were neurological or 
thrombotic disease/risk factors (Figure 1).
Blood samples
Blood samples were collected from patients within two days 
of the acute ischemic cerebrovascular event. At the time of 
blood sampling, the children were medication-free. Blood 
samples of control participants were collected at the same 
time when venepunction was performed for preoperative 
blood tests examination. Blood samples of all participants 
were taken according to good laboratory practice (15).
Blood for coagulation analysis was drawn into Vacutain-
er tubes containing 0.109 M buffered sodium citrate, 
and centrifuged within 30 minutes twice at 2000 g for 
15 minutes at room temperature. Functional activities of 
antithrombin III and protein C were tested immediately, 
whereas plasma sample aliquots for the determination of 
free protein S antigen and the presence of lupus antico-
agulant (LA) were stored at -35°C, and assayed in batches. 
In cases when results of laboratory tests PC and free PS 
were pathological (according to age-specific reference 
interval), blood sampling to determine these parameters 
was repeated after three to six months at the regular neu-
ropediatric examination (16).
For the determination of fasting homocysteine (Hcy), 
blood was collected into tubes containing K3-EDTA, placed 
immediately on ice, and centrifuged within 30 minutes at 
1500 g for 5 minutes. Plasma samples were stored at -20°C 
until assaying.
Blood for serum samples was drawn into Vacutainer tubes 
without additives. Serum samples for the determination of 
Lp (a), triglycerides, total cholesterol, high- and low-den-
sity lipoprotein (HDL- and LDL-cholesterol), anticardiolipin 
FiguRe 1. study population, inclusion/exclusion criteria, and participants enrolled 
in the study. Ais – arterial ischemic stroke; tiA – transient ischemic attacks; Ct – 
computed tomography; MRi – magnetic resonance imaging; eeg – electroenceph-
alography; tCCD – transcranial color Doppler ultrasonography.
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(aCA), and antiphosphatidyl-serine (aPS) antibodies were 
aliquoted and stored at -20°C until assaying. For genetic 
analysis, EDTA whole blood samples were frozen at -20°C 
until DNA extraction.
Assays
Functional activities of antithrombin III and protein C, us-
ing chromogenic assays, were measured on a Sysmex CA-
500 coagulation analyzer (Siemens Medical Solutions Di-
agnostics, IL, Deerfield, USA). Free protein S antigen was 
determined by enzyme-linked immunosorbent assay (ELI-
SA) according to the method of Comp et al (17). The pres-
ence of LA was determined according to the criteria of the 
Scientific and Standardization Committee of the Interna-
tional Society on Thrombosis and Hemostasis (18). Deter-
mination of aCA and aPS (IgA, IgG, and IgM isotypes) was 
performed by using commercially available ELISA assays 
(Euroimmun AG, Lübeck, Germany).
Fasting total plasma Hcy was measured using the fluo-
rescence polarization immunoassay method on the IMx 
analyzer (Abbott Diagnostics, Abbott Park, IL, USA). Total 
cholesterol and triglycerides were measured using stan-
dard enzymatic methods, while HDL-cholesterol was de-
termined using a homogenous direct method (Olympus 
Diagnostics, GmbH, Hamburg, Germany). LDL-cholester-
ol levels were calculated using the Friedewald equation, 
whereas lipoprotein (a) concentrations were measured us-
ing the immunoturbidimetric method (Roche Diagnostics, 
Basel, Switzerland).
Results of coagulation analyses, tHcy, triglycerides, total 
cholesterol, HDL- and LDL-cholesterol were classified ac-
cording to age-specific reference intervals (19-23). Serum 
concentrations of lipoprotein (a)>0.3 g/L were regarded as 
elevated, according to previously identified threshold val-
ue for venous thrombosis in childhood and increased cere-
brovascular and cardiovascular risk in adults (24,25). For all 
aCA and aPS isotypes, cut-off values were calculated and 
considered as positive for value over the 99th percentile 
for normal subjects (26).
Genomic DNA was extracted according to standard pro-
cedures using the salting-out method (27). Factor V Le-
iden and the FII 20210A were determined by polymerase 
chain reaction-restriction fragment length polymorphism 
(PCR-RFLP) method. A 287-bp fragment encompassing 
nucleotide position 1691 of factor V gene was amplified 
with primers, according to Zöller et al (28). After the di-
gestion with MnlI (Stratagene, Austin, TX, USA), the wild 
type allele (1691G allele) resulted in 37-bp, 93-bp, and 
157-bp fragments, whereas the mutant allele (1691A al-
lele) resulted in 130-bp and 157-bp fragments. Analysis for 
FII 20210A was performed according to the method de-
scribed by Poort et al (29). After the digestion of amplified 
345-bp fragments with Hind III (Roche Diagnostics, Man-
tABLe 1. Applied reference intervals (by age and sex) or used 
cut-off values of studied risk factors
Age Limit




>6 mo and adults <75.0




>6 mo and adults <75.0











Cholesterol, high density lipoprotein (mmol/L)
<18 y <0.9













Polymorphisms FVL and F ii 20210A
<18 y AA, GA:GG*
*“Dominant” model: homozygous (AA) or heterozygous (gA) variant 
in comparison with the homozygous wild-type (gg).
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tABLe 2. Distribution of prothrombotic risk factors in patients and control group. obtained values are given as counts and percent-









Antithrombin III (%)  3 (6.4)  0 (0.0)  0 (0.0)
Protein C (%)  6 (12.8)  8 (10.4)  0 (0.0)
Free protein S antigen (%)  3 (6.4)  9 (11.7)  0 (0.0)
Total of factors 12 17  0
number of patients with
0 factors 39 (83.0) 62 (80.5) 42(100.0)
1 factor  6 (12.8) 13 (16.9)  0 (0.0)
2 factors  3 (6.4)  2 (2.6)  0 (0.0)
Total of patients with any factor  9 (19.1) 15 (19.5)  0 (0.0)
Blood coagulation factors
FV Leiden
GA heterozygote  2 (4.3)  3 (3.9)  2 (4.8)
AA homozygote  0 (0.0)  0 (0.0)  0 (0.0)
Fii 20210A
GA heterozygote  2 (4.3)  2 (2.6)  1 (2.4)
AA homozygote  0 (0.0)  0 (0.0)  0 (0.0)
Total of factors  4  5  3
number of patients with
0 factors 44 (93.6) 72 (93.5) 39 (92.9)
1 factor  2 (4.3)  5 (6.5)  3 (7.1)
2 factors  1 (2.1)  0 (0.0)  0 (0.0)
Total of patients with any factor  3 (6.4)  5 (6.5)  3 (7.1)
Homocysteine (μmol/L)  7 (14.9)  9 (11.7)  5 (11.9)
Lipid and lipoprotein profile 15 (31.9) 24 (31.2) 10 (23.8)
Triglycerides (mmol/L)  5 (10.6)  2 (2.6)  1 (2.4)
Total cholesterol (mmol/L)  3 (6.4)  0 (0.0)  1 (2.4)
High density lipoprotein-cholesterol (mmol/L)  4 (8.5)  7 (9.1)  2 (4.8)
Low density lipoprotein-cholesterol (mmol/L)  5 (10.6)  1 (1.3)  2 (4.8)
Total of factors 32 34 16
number of patients with
0 factors 26 (55.3) 47 (61.0) 29 (69.0)
1 factor 12 (25.5) 27 (35.0) 11 (26.2)
2 factors  7 (14.9)  2 (2.6)  1 (2.4)
3 factors  2 (4.3)  1 (1.3)  1 (2.4)
Total of patients with any factor  21(44.7) 30 (39.0) 13 (31.0)
Antiphospholipid antibodies
Anticardiolipin antibodies  0 (0.0)  1 (1.3)  3 (7.1)
IgG  0  1  1
IgA  0  0  1
IgM  0  0  1
Antiphosphatidyl-serine antibodies  4 (8.5)  0 (0.0)  1 (2.4)
IgG  4  0  0
IgA  0  0  0
IgM  0  0  0
Lupus anticoagulant  0 (0.0)  0 (0.0)  (0.0)
Total of factors  4  1  4
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nheim, Germany), the mutant A allele was cleaved in two 
23-bp and 322-bp fragments, whereas the wild type G al-
lele remained undigested. Digested PCR products were 
separated by electrophoresis on 1.5% agarose gels (Ap-
plied Biosystems, Foster City, CA, USA) for factor V Leiden 
and on Spreadex gels (Guest Elchrom Scientific, Cham, 
Switzerland) for FII 20210A.
All measured prothrombotic risk factors were classified 
into five groups: natural coagulation inhibitors (antithrom-
bin III, protein C, free protein S antigen), blood coagulation 
factors mutations (FVL and FII 20210A), homocysteine, lipid 
and lipoprotein profile (lipoprotein (a), triglycerides, total 
cholesterol, HDL- and LDL-cholesterol), and APA group fac-
tors (LA, aCA, and aPS).
Presentation of results
Results are presented as relative frequencies of all observed 
variables (proportion and percentage). Pathological values 
represent the values outside of the applied reference in-
tervals (by age and sex) or cut-off values (Table 1). Patho-
logical value of polymorphisms FVL and F II 20210 was the 
“dominant” model (homozygous or heterozygous variant 
in comparison to the homozygous wild-type). Statistical 
analysis of the results was not performed because control 
group did not match by age and sex.
ResuLts
Out of 124 children, the diagnosis of AIS was established 
in 47 children (30 boys, 17 girls), median age 7 years (6 
months-18 years). The remaining 77 children (33 boys, 
44 girls) were diagnosed with TIA (median age 12 years) 
(3-18). The control group included 42 healthy children (32 
boys and 10 girls with median age of 10 years and range 
from 3.5 to 18 years).
Patients and controls most frequently had pathological val-
ues of the prothrombotic risk factors in the lipid and lipo-
protein profile group, followed by the natural coagulation 
inhibitors, tHcy, blood coagulation factor polymorphisms, 
and APA group (Table 2).
We found 32 pathological values in the lipids and lipopro-
teins group in 21/47 children with AIS (44.7%), and 2 or 
3 values in 9 children (Table 2). Similarly, in children with 
TIA we found 34 pathological values in the lipids and li-
poproteins group in 30/77 children (39.0%) and 2 or 3 val-
ues in 3 children. Two out of 13/42 (31.0%) healthy children 
showed the presence of multiple pathological values of 
lipid/lipoproteins.
In this group of risk factors, the risk factor with most fre-
quent pathological values was lipoprotein (a), which usu-
ally occurred in combination with elevated LDL-choles-
terol (3/5) and elevated triglycerides (4/5) in children with 
AIS. In children with TIA and the control group, elevated 
levels of lipoprotein (a) were mostly an independent fac-
tor and were found in combination with lower HDL-cho-
number of patients with:
0 factors 43 (91.5) 76 (98.7) 38 (80.9)
1 factor  4 (8.5)  1 (1.3)  2 (4.8)
2 factors  0 (0.0)  0 (0.0)  1 (2.4)
Total of patients with any factor  4 (8.5)  1 (1.3)  3 (7.1)
tABLe 2. Continued. Distribution of prothrombotic risk factors in patients and control group. obtained values are given as counts 








FiguRe 2. the percentage of participants with simultaneously 
present prothrombotic risk factors. in the control group there 
were no cases with three or more simultaneously present 
prothrombotic risk factors. Ais – arterial ischemic stroke; tiA – 
transient ischemic attacks.
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lesterol and elevated LDL-cholesterol levels only in indi-
vidual cases.
In the group of natural coagulation inhibitors, patholog-
ical values were found in 9/47 (19.1%) of children with 
AIS, 15/77 (19.5%) children with TIA and in no children 
in the control group. In most cases, decreased value of 
antithrombin III, protein C, and free protein S were inde-
pendent factors. Two patients with AIS and TIA had a de-
creased value of protein C and protein S at the same time, 
and only one child with AIS had a decreased value of PC 
and antithrombin III.
Elevated homocysteine concentrations, the presence of 
FVL and FII 20210 polymorphisms as well as the presence of 
antiphospholipid antibodies were equally represented in all 
groups. All children with FVL and FII 20210A were heterozy-
gous and one child in the AIS group had both polymor-
phisms. The overall representation of risk factors from the 
APA group was small. In all patients, LA was negative.
Forty-five out of 124 (36.3%) children with AIS/TIA and 
20/42 (47.6%) controls did not have any prothrombotic risk 
factor. The presence of one or two risk factors at the same 
time was found in all groups, but the presence of three or 
more at same time was found only in children with AIS and 
TIA (14/124; 11.3%).(Figure 2)
DisCussion
The most common prothrombotic risk factor in our study 
was elevated lipoprotein (a). About one third of children 
with AIS and TIA and about fifth of controls had pathologi-
cal values of lipoprotein (a). Previously published child-
hood stroke reports found elevated values of lipoprotein 
(a) in between 15% and 29% of examinees (10,14,30-32). 
The same studies reported a lower proportion of elevated 
lipoprotein (a) in the control group than in our study. The 
reason for this may be non-standardized determination 
methods and reference values (33).
Low-activity natural coagulation inhibitors in our study 
had frequencies from 6.4% to 12.8%, with the lowest fre-
quency of antithrombin III and approximately the same 
frequency of protein C and free protein S in children with 
AIS and TIA. In the control group, there were no cases 
with low activities of natural coagulation inhibitors. Such 
results are in accordance with previously published 
data (10,13,14,31,32,34). These studies suggest that 
only protein C can be used as a risk factor for child-
hood AIS. However, our results show that both protein 
C and protein S could be prothrombotic risk factors for 
cerebrovascular events (AIS and TIA).
Frequencies of FVL and FII 20210 in our study were lower 
than some previously published (31,33), but in the same 
range as those found in a recent meta-analysis (13,14) 
and similar to those recently published in the neighbor-
ing region (35,36).
To our knowledge, this is the first study in children with 
AIS that included aPS in the prothrombotic workup, be-
sides the two most commonly tested APAs, LA and aCA. 
Although the presence of APA (especially aCA) has been 
reported to be associated with a 6-fold risk of stroke in 
children (11) and aPS has been reported to be a new pro-
thrombotic risk factor and involved in the etiology of AIS 
(37-39), the number of positive aCA and aPS in our study 
was small and LA was negative in all participants.
Our study showed that multiple investigated risk factors 
could be a common hallmark of cerebrovascular disor-
ders in children. The presence of one or two risk factors in 
the same child was found in all investigated groups, but 
the simultaneous presence of three or more factors was 
found only among children with AIS and TIA. This finding 
cannot be compared with previous findings for three rea-
sons: 1) meta-analyses provide information on just two 
or more simultaneous risk factors (10,13,14,30) and some 
of them include other known risk factors, not only pro-
thrombotic ones (40); 2) there are individual studies in-
volving specific and smaller panels of risk factors (9,35); 
and 3) there are no published data about the frequency 
of prothrombotic risk factors in children with TIA, except 
in one study with only inherited prothrombotic risk fac-
tors (36).
An important limitation of this study is the control group 
because the number of healthy children was small and they 
were not matched with patients according to age and sex. 
The reason for this was mostly the need to reduce blood 
sampling since frequent blood sampling in preschool chil-
dren can lead to anemia and very rare adenotonsillecto-
mies under 3 years of age.
In conclusion, the presence of multiple prothrombotic risk 
factors in children with cerebrovascular disorder suggests 
that a combination of risk factors rather than individual risk 
factors could contribute to cerebrovascular disorders in 
children (AIS/TIA).
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